30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

DJO 2Q19 Growth Driven by Joint Replacement Sales -



  • Colfax leadership is pleased with the continuing integration of DJO, noting “good engagement and associate feedback”
  • Joint replacement growth driven by product innovation and relationships with key opinion leaders, including positive surgeon response to the EMPOWR knee
  • Colfax’s operations improvement plan for DJO includes continuous improvement of procurement and supply chain, with a focus on the reimbursement process and product innovation
  • Leadership noted that the DJO purchase gives them new directions to pursue acquisitions that can improve both the scale and reach of Colfax


Performance by Segment

ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):

  2Q19 2Q18 $ Chg % Chg
Joint Replacement $81.8 $73.4 $8.4 11.5%
   Knees $21.2 $19.2 $2.0 10.5%
   Hips $18.0 $16.6 $1.4 8.4%
   Extremities $42.6 $37.6 $5.0 13.4%
Other (Recovery Sciences) $22.4 $22.5 $0.0 -0.1%
Total $104.3 $95.8 $8.4 8.8%


Sources: Colfax Corp.; ORTHOWORLD estimates.

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.